I'm confident that biota has a bright future. In a year or two...

I'm confident that biota has a bright future. In a year or two current events will be mostly forgotten. A key value driver is listing on the Nasdaq. The merger option is costly from a biota shareholder lens, the dilution is massive.

Anyhow, the fundamentals of the stockpiling market are strong and progression of other pipeline drugs have been positive.

NABI shareholders are quite weak, if they were biotech savvy they wouldn't be NABI holders! Hence the stated benefit of the merger, acquiring an existing shareholder presence is just not that valuable.

Anyhow, patience is the key virtue now.